Pfizer and Biovac partner to produce Covid-19 vaccine in Africa

Pfizer-BioNTech’s Covid-19 vaccine is approved for emergency use by individuals over the age of 12. Credits: Unsplash’s Jesse Paul

Pfizer and BioNTech have signed an agreement with South African biopharmacy company Biovac Institute to produce the Covid-19 vaccine for supply in the African Union.

This vaccine is approved for emergency use for active immunization to prevent Covid-19 in people over the age of 12.

Under the agreement, Biovac will carry out production and distribution activities within Pfizer and BioNTech’s international Covid-19 vaccine supply chain and manufacturing network.

Currently, the network covers three continents and consists of approximately 20 manufacturing sites.

Pfizer and BioNTech will immediately begin technology transfer, on-site development, and equipment installation work to support Biovac’s participation in vaccine production.

The two companies plan to integrate Biovac’s Cape Town plant into the vaccine supply chain by the end of this year.

Biovac will source the drug substance from a European site and will begin production of the final dose next year.

With full capacity, the company can produce more than 100 million final doses annually.

Pfizer said all vaccine doses produced by Biovac will be supplied in 55 African Union member countries.

Ugur Sahin, CEO and co-founder of BioNTech, said: “We aim to ensure that vaccines can be manufactured and distributed by people on all continents, while ensuring the quality and dosage of the manufacturing process.

“We believe our mRNA technology can be used to develop vaccine candidates that address other diseases, which is why we continue to evaluate sustainable approaches that support the development and production of mRNA vaccines on the African continent. is.”

To date, Pfizer and BioNTech have exported approximately 1 billion Covid-19 vaccines to more than 100 countries around the world.

Contract manufacturers are selected by companies based on a variety of factors, including quality, compliance, safety performance, technical capabilities, and capacity availability.

Last week, the US Food and Drug Administration Priority examination designation given to biologics license application Submitted by Pfizer and BioNTech for the Covid-19 vaccine. Pfizer and Biovac partner to produce Covid-19 vaccine in Africa

Back to top button